Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

About Sucampo Pharmaceuticals (NASDAQ:SCMP)

Sucampo Pharmaceuticals logoSucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:SCMP
  • CUSIP: 86490910
  • Web:
  • Market Cap: $494.84 million
  • Outstanding Shares: 46,464,000
Average Prices:
  • 50 Day Moving Avg: $10.20
  • 200 Day Moving Avg: $12.17
  • 52 Week Range: $9.30 - $17.55
  • Trailing P/E Ratio: 17.75
  • Foreward P/E Ratio: 9.51
  • P/E Growth: 0.73
Sales & Book Value:
  • Annual Revenue: $239.13 million
  • Price / Sales: 2.07
  • Book Value: $4.01 per share
  • Price / Book: 2.66
  • EBIDTA: $128.05 million
  • Net Margins: 6.29%
  • Return on Equity: 44.19%
  • Return on Assets: 10.98%
  • Debt-to-Equity Ratio: 1.36%
  • Current Ratio: 3.56%
  • Quick Ratio: 3.19%
  • Average Volume: 827,687 shs.
  • Beta: 1.74
  • Short Ratio: 5.16

Frequently Asked Questions for Sucampo Pharmaceuticals (NASDAQ:SCMP)

What is Sucampo Pharmaceuticals' stock symbol?

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

How were Sucampo Pharmaceuticals' earnings last quarter?

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its quarterly earnings results on Wednesday, May, 3rd. The company reported $0.23 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.28 by $0.05. The company earned $56.30 million during the quarter, compared to analyst estimates of $54.15 million. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.21 EPS. View Sucampo Pharmaceuticals' Earnings History.

When will Sucampo Pharmaceuticals make its next earnings announcement?

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

What guidance has Sucampo Pharmaceuticals issued on next quarter's earnings?

Sucampo Pharmaceuticals issued an update on its FY17 earnings guidance on Wednesday, March, 8th. The company provided earnings per share guidance of $1.35-1.50 for the period, compared to the Thomson Reuters consensus estimate of $1.44. The company issued revenue guidance of $220-230 million, compared to the consensus revenue estimate of $228.21 million.

Where is Sucampo Pharmaceuticals' stock going? Where will Sucampo Pharmaceuticals' stock price be in 2017?

6 analysts have issued 12-month target prices for Sucampo Pharmaceuticals' stock. Their predictions range from $11.00 to $27.00. On average, they expect Sucampo Pharmaceuticals' share price to reach $17.17 in the next year. View Analyst Ratings for Sucampo Pharmaceuticals.

What are analysts saying about Sucampo Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

  • 1. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
  • 2. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
  • 3. According to Zacks Investment Research, "Sucampo’s earnings and revenues beat expectations in the fourth quarter of 2016. However, Sucampo’s dependence on its sole marketed product Amitiza for growth is concerning. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. Shares of the company have underperformed the Medical-Drugs industry year to date. The company is focused on expanding Amitiza’s label and penetrating into new markets. The company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza bodes well for the company. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America." (3/10/2017)
  • 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Who are some of Sucampo Pharmaceuticals' key competitors?

Who owns Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include LSV Asset Management (5.41%), Dimensional Fund Advisors LP (3.58%), Vanguard Group Inc. (3.36%), Renaissance Technologies LLC (2.56%), Royce & Associates LP (2.24%) and Redwood Investments LLC (1.39%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Matthias Alder, Peter Greenleaf and Thomas J Knapp. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Who sold Sucampo Pharmaceuticals stock? Who is selling Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Metropolitan Life Insurance Co. NY, Teachers Advisors LLC, Renaissance Technologies LLC, Alliancebernstein L.P., Acadian Asset Management LLC, Prudential Financial Inc. and Oxford Asset Management. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Who bought Sucampo Pharmaceuticals stock? Who is buying Sucampo Pharmaceuticals stock?

Sucampo Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., LSV Asset Management, Royce & Associates LP, Bank of New York Mellon Corp, Principal Financial Group Inc., Gotham Asset Management LLC, Cornerstone Capital Management Holdings LLC. and Seizert Capital Partners LLC. View Insider Buying and Selling for Sucampo Pharmaceuticals.

How do I buy Sucampo Pharmaceuticals stock?

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sucampo Pharmaceuticals stock cost?

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $10.65.

Analyst Ratings

Consensus Ratings for Sucampo Pharmaceuticals (NASDAQ:SCMP) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $17.17 (61.19% upside)

Analysts' Ratings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/4/2017Jefferies Group LLCLower Price TargetHold$13.00 -> $11.00MediumView Rating Details
4/13/2017Maxim GroupReiterated RatingBuy$21.00MediumView Rating Details
4/4/2017MizuhoReiterated RatingBuy$14.00HighView Rating Details
3/11/2017Roth CapitalSet Price TargetBuy$27.00MediumView Rating Details
3/10/2017WallachBeth CapitalLower Price TargetBuy$20.00 -> $15.00LowView Rating Details
9/7/2016Northland SecuritiesInitiated CoverageOutperform$15.00N/AView Rating Details
5/4/2016GuggenheimReiterated RatingBuy$29.00N/AView Rating Details
3/17/2016Leerink SwannReiterated RatingMarket Perform$17.00N/AView Rating Details
11/6/2015HC WainwrightLower Price Target$36.00 -> $28.00N/AView Rating Details
(Data available from 5/23/2015 forward)


Earnings History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Earnings History by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017$0.28$0.23$54.15 million$56.30 millionViewListenView Earnings Details
3/8/2017Q4 2016$0.48$0.68$66.00 million$73.00 millionViewListenView Earnings Details
11/9/2016Q316$0.26$0.28$51.30 million$57.90 millionViewListenView Earnings Details
8/3/2016Q216$0.22$0.23$48.33 million$52.00 millionViewListenView Earnings Details
5/4/2016Q116$0.19$0.21$44.11 million$47.20 millionViewListenView Earnings Details
3/8/2016Q415$0.19$0.43$42.72 million$55.40 millionViewListenView Earnings Details
11/4/2015Q315$0.18$0.16$36.18 million$33.50 millionViewListenView Earnings Details
8/5/2015Q215$0.15$0.21$31.90 million$34.90 millionViewListenView Earnings Details
5/6/2015Q114$0.14$0.14$30.19 million$29.50 millionViewListenView Earnings Details
3/4/2015Q413$0.17$0.21$37.23 million$37.80 millionViewListenView Earnings Details
11/6/2014Q313$0.04$0.03$26.11 million$31.50 millionViewListenView Earnings Details
8/5/2014Q213$0.03$0.04$24.06 million$24.10 millionViewListenView Earnings Details
5/7/2014Q113$0.04$0.02$24.19 million$22.20 millionViewListenView Earnings Details
2/26/2014Q4($0.04)$0.06$22.75 million$24.50 millionViewListenView Earnings Details
3/13/2013Q4 2012$0.12$0.32$32.21 million$34.90 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)
2017 EPS Consensus Estimate: $1.07
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.23$0.29$0.25
Q2 20172$0.22$0.26$0.24
Q3 20172$0.26$0.27$0.27
Q4 20172$0.29$0.33$0.31
(Data provided by Zacks Investment Research)


Dividend History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Ownership Percentage: 3.31%
Institutional Ownership Percentage: 41.56%
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Insider Trades by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016Daniel P GetmanDirectorSell20,000$16.86$337,200.00View SEC Filing  
11/29/2016Peter GreenleafCEOSell200,000$16.84$3,368,000.00View SEC Filing  
11/28/2016Matthias AlderEVPSell150,000$16.00$2,400,000.00View SEC Filing  
11/15/2016Andrew P SmithCFOSell1,766$15.58$27,514.28View SEC Filing  
8/28/2015Daniel P. GetmanDirectorSell30,000$28.14$844,200.00View SEC Filing  
7/20/2015Thomas J KnappInsiderSell64,528$23.43$1,511,891.04View SEC Filing  
3/12/2015William AshtonDirectorSell55,762$17.55$978,623.10View SEC Filing  
3/11/2015Anthony C CelesteDirectorSell65,966$17.34$1,143,850.44View SEC Filing  
12/16/2014Cary J ClaiborneCFOSell50,000$12.91$645,500.00View SEC Filing  
12/15/2014Cary J ClaiborneCFOSell7,100$12.89$91,519.00View SEC Filing  
8/7/2014Sachiko KunoMajor ShareholderSell181,727$6.28$1,141,245.56View SEC Filing  
8/4/2014Ryuji UenoMajor ShareholderSell140,873$6.02$848,055.46View SEC Filing  
7/31/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/30/2014S&R Technology Holdings, LlcMajor ShareholderSell300$6.25$1,875.00View SEC Filing  
7/25/2014Ryuji UenoMajor ShareholderSell16,155$6.26$101,130.30View SEC Filing  
7/23/2014Ryuji UenoMajor ShareholderSell5,845$6.29$36,765.05View SEC Filing  
7/22/2014S&R Technology Holdings, LlcMajor ShareholderSell2,500$6.25$15,625.00View SEC Filing  
7/21/2014S&R Technology Holdings, LlcMajor ShareholderSell100$6.25$625.00View SEC Filing  
7/18/2014S&R Technology Holdings, LlcMajor ShareholderSell15,000$6.27$94,050.00View SEC Filing  
4/29/2014S&R Technology Holdings, Llcmajor shareholderSell113,600$6.65$755,440.00View SEC Filing  
4/25/2014Sachiko Kunomajor shareholderSell118,700$6.69$794,103.00View SEC Filing  
3/18/2014Gayle DolecekDirectorSell1,200$8.03$9,636.00View SEC Filing  
2/27/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
1/17/2014Ryuji UenoCEOSell360,000$10.36$3,729,600.00View SEC Filing  
1/7/2014Cary ClaiborneCFOSell2,500$9.00$22,500.00View SEC Filing  
10/16/2013Sachiko KunoMajor ShareholderSell360,000$6.35$2,286,000.00View SEC Filing  
9/18/2013Ryuji UenoCEOSell38,462$5.69$218,848.78View SEC Filing  
9/3/2013Ryuji UenoCEOSell38,462$5.59$215,002.58View SEC Filing  
8/19/2013Ryuji UenoCEOSell38,462$6.04$232,310.48View SEC Filing  
8/6/2013Sachiko Kunomajor shareholderSell38,462$6.21$238,849.02View SEC Filing  
7/24/2013Ryuji UenoCEOSell38,462$6.52$250,772.24View SEC Filing  
7/9/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.48$249,233.76View SEC Filing  
6/24/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$6.61$254,233.82View SEC Filing  
6/10/2013Sachiko KunoMajor ShareholderSell38,462$7.29$280,387.98View SEC Filing  
5/28/2013Ryuji UenoCEOSell38,462$8.79$338,080.98View SEC Filing  
5/21/2013Cary J ClaiborneCFOSell4,640$9.52$44,172.80View SEC Filing  
5/20/2013Stanley G MieleSVPSell6,400$9.60$61,440.00View SEC Filing  
5/16/2013Stanley G MieleSVPSell48,600$9.67$469,962.00View SEC Filing  
5/15/2013Timothy I MaudlinDirectorBuy32,870$9.82$322,783.40View SEC Filing  
5/13/2013Sachiko KunoMajor ShareholderSell38,462$9.27$356,542.74View SEC Filing  
2/4/2013S&R Technology Holdings, LlcMajor ShareholderSell38,462$5.22$200,771.64View SEC Filing  
12/26/2012S&R Technology Holdings, LlcMajor ShareholderSell20,262$5.01$101,512.62View SEC Filing  
11/27/2012Sachiko KunoMajor ShareholderSell12,205$5.00$61,025.00View SEC Filing  
11/13/2012Sachiko KunoMajor ShareholderSell11,962$5.00$59,810.00View SEC Filing  
11/1/2012Sachiko KunoMajor ShareholderSell37,595$5.06$190,230.70View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Sucampo Pharmaceuticals (NASDAQ:SCMP)
Latest Headlines for Sucampo Pharmaceuticals (NASDAQ:SCMP)
DateHeadline logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Average Rating of "Buy" from Analysts - May 15 at 11:10 AM logoCerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors - May 15 at 9:29 AM logoSucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : May 12, 2017 - May 12 at 8:24 PM logoSucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May 11, 2017 - May 11 at 8:11 PM logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference - May 11 at 8:11 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Forecasted to Earn FY2017 Earnings of $1.01 Per Share - May 8 at 9:38 AM logoQ2 2017 EPS Estimates for Sucampo Pharmaceuticals, Inc. Cut by Jefferies Group (SCMP) - May 5 at 8:02 AM logoSucampo Pharmaceuticals, Inc. (SCMP) Rating Reiterated by Jefferies Group LLC - May 4 at 1:20 PM logoSucampo Reports First Quarter 2017 Financial Results - May 4 at 12:12 AM logoEdited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT - May 4 at 12:12 AM logoInvestor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call - May 3 at 7:11 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Posts Earnings Results, Misses Estimates By $0.04 EPS - May 3 at 6:04 PM logoSucampo tops 1Q revenue forecasts - May 3 at 7:02 AM logoSomewhat Favorable Press Coverage Likely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price - May 3 at 1:03 AM logoSucampo Pharmaceuticals, Inc. (SCMP) to Release Earnings on Wednesday - May 1 at 7:42 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Expected to Post Earnings of $0.25 Per Share - April 29 at 1:22 AM logoSucampo Pharmaceuticals (SCMP) Getting Favorable Press Coverage, AlphaOne Reports - April 27 at 6:14 PM logoLeerink Swann Equities Analysts Decrease Earnings Estimates for Sucampo Pharmaceuticals, Inc. (SCMP) - April 27 at 1:00 PM logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference - April 26 at 9:01 PM logoCommit To Buy Sucampo Pharmaceuticals At $7.50, Earn 17% Annualized Using Options - - April 26 at 4:00 PM logoETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017 - April 26 at 4:00 PM logoLeerink Swann Weighs in on Sucampo Pharmaceuticals, Inc.'s Q1 2017 Earnings (SCMP) - April 26 at 8:20 AM logoSucampo Pharmaceuticals (SCMP) Earns Daily News Sentiment Score of 0.21 - April 24 at 7:42 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Given a $13.00 Price Target at Jefferies Group LLC - April 21 at 4:20 PM logoSucampo Pharma (SCMP) Confirms New Study Published in PLOS ONE Advances Science on VTS-270 for Treatment ... - - April 20 at 8:19 AM logo3 Fascinating Small-Cap Biotech Stocks To Watch - April 19 at 9:25 AM logoSucampo Announces First Quarter 2017 Earnings Call - April 19 at 9:25 AM logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Recommendation of "Buy" from Brokerages - April 18 at 11:18 AM logoNew Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 - April 18 at 9:18 AM logoSomewhat Positive Media Coverage Very Likely to Affect Sucampo Pharmaceuticals (SCMP) Stock Price - April 17 at 7:25 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Sees Large Increase in Short Interest - April 16 at 12:22 AM logoSucampo Pharmaceuticals (SCMP) Receiving Very Positive Press Coverage, Analysis Finds - April 14 at 10:50 AM logoSucampo Pharmaceuticals, Inc. (SCMP) PT Set at $21.00 by Maxim Group - April 13 at 8:08 PM logoSucampo Pharmaceuticals Acquires Vtesse For $200 Million Plus Royalties - April 10 at 7:15 PM logoSucampo (SCMP) Down 7.6% Since Earnings Report: Can It Rebound? - April 10 at 9:18 AM logoZacks: Analysts Expect Sucampo Pharmaceuticals, Inc. (SCMP) Will Announce Quarterly Sales of $53.47 Million - April 9 at 8:36 AM logoZacks: Analysts Expect Sucampo Pharmaceuticals, Inc. (SCMP) to Announce $0.26 EPS - April 7 at 4:47 PM logoSucampo Pharmaceuticals (SCMP) Presents At 16th Annual Needham Healthcare Conference - Slideshow - April 7 at 12:29 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Earns "Buy" Rating from Maxim Group - April 6 at 2:42 PM logoSucampo Pharmaceuticals' (SCMP) Buy Rating Reaffirmed at Mizuho - April 4 at 11:49 PM logoSucampo Pharmaceuticals, Inc.: Sucampo Acquires Vtesse Inc. - April 3 at 7:19 PM logoSucampo just bought this local rare disease company for $200M - April 3 at 7:19 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Rating Reiterated by Maxim Group - April 3 at 4:28 PM logoSucampo Pharma (SCMP) to Acquire Vtesse for $200M - - April 3 at 8:43 AM logoSucampo Acquires Vtesse Inc. - April 3 at 8:43 AM logo6:31 am Sucampo Pharma acquires privately-held Vtesse for upfront consideration of $200 mln; funds the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; updates FY17 guida - April 3 at 8:43 AM logoSUCAMPO PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisiti - April 3 at 8:43 AM logoSucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference - March 28 at 7:35 PM logoSucampo Pharmaceuticals, Inc. (SCMP) Receives Consensus Rating of "Buy" from Analysts - March 23 at 11:49 AM logoJefferies Group LLC Lowers Sucampo Pharmaceuticals, Inc. (SCMP) Price Target to $13.00 - March 23 at 10:05 AM


Sucampo Pharmaceuticals (SCMP) Chart for Tuesday, May, 23, 2017

This page was last updated on 5/23/2017 by Staff